Publication
Long-Term and Concentration-Dependent Beneficial Effect of Efavirenz on HDL-Cholesterol in HIV-Infected Patients
| dc.contributor.author | Pereira, SA | |
| dc.contributor.author | Branco, T | |
| dc.contributor.author | Côrte-Real, R | |
| dc.contributor.author | Germano, I | |
| dc.contributor.author | Lampreia, F | |
| dc.contributor.author | Caixas, U | |
| dc.contributor.author | Monteiro, E | |
| dc.date.accessioned | 2014-04-08T11:52:21Z | |
| dc.date.available | 2014-04-08T11:52:21Z | |
| dc.date.issued | 2006 | |
| dc.description.abstract | AIMS: To investigate the long-term effects of efavirenz on cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein (LDL-C) and triglycerides (TG). METHODS: Thirty-four HIV-infected patients who commenced efavirenz therapy were monitored for 36 months. RESULTS: In patients with baseline HDL-C<40 mg.dL-1 an increase in HDL-C from 31+/-1 mg.dL-1 to 44+/-2 mg.dL-1 (95% confidence interval 5.9, 21.9, P<0.01) was observed and remained throughout the follow-up period. Median efavirenz plasma concentration was 1.98 mg.L-1 and a direct correlation between percentage of HDL-C variation or TC/HDL-C ratio and efavirenz plasma concentrations was found. CONCLUSIONS: There is evidence of a long-term and concentration-dependent beneficial effect of efavirenz on HDL-C in HIV-infected patients. | por |
| dc.identifier.citation | Br J Clin Pharmacol. 2006 May;61(5):601-4 | por |
| dc.identifier.uri | http://hdl.handle.net/10400.17/1777 | |
| dc.language.iso | eng | por |
| dc.peerreviewed | yes | por |
| dc.publisher | Wiley | por |
| dc.subject | CHLC MED | por |
| dc.subject | Benzoxazinas | por |
| dc.subject | Colesterol | por |
| dc.subject | Colesterol HDL | por |
| dc.subject | Relação Dose-Resposta a Medicamento | por |
| dc.subject | Estudos de Follow-Up | por |
| dc.subject | Glicoproteínas | por |
| dc.subject | Infecção por HIV | por |
| dc.subject | HIV-1 | por |
| dc.subject | Oxazinas | por |
| dc.subject | Estudos Prospectivos | por |
| dc.subject | Inibidores de Transcriptase Reversa | por |
| dc.subject | Factores de Tempo | por |
| dc.subject | Resultado de Tratamento | por |
| dc.title | Long-Term and Concentration-Dependent Beneficial Effect of Efavirenz on HDL-Cholesterol in HIV-Infected Patients | por |
| dc.type | journal article | |
| dspace.entity.type | Publication | |
| oaire.citation.endPage | 604 | por |
| oaire.citation.startPage | 601 | por |
| oaire.citation.title | British Journal of Clinical Pharmacology | por |
| rcaap.rights | openAccess | por |
| rcaap.type | article | por |